ArticleFrontiers in immunology2026
Immune profiling shows limited systemic changes in children with autism after autologous cord blood transfusion.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Autism spectrum disorder (ASD or autism) is a neurodevelopmental condition characterized by social difficulties and restricted, repetitive behaviors, and is a leading cause of morbidity in children and adolescents. Immune dysregulation, including neuroinflammation, brain autoantibodies, and altered adaptive responses, has been implicated in autism pathophysiology. To address these immune alterations, autologous cord blood transfusion has been proposed as a therapy, given its abundance of immune regulatory cells and lack of rejection risk. Methods: Using multi-parametric mass cytometry, we profiled the peripheral blood mononuclear cells from children with autism at pre-transfusion and 6 months post-transfusion to assess the effects of this intervention on effector and regulatory subsets. Results: Our results showed that transfusion did not increase regulatory T or B cells. However, there was a decrease in CD4+ Central Memory (CM) T cells and memory B cells 6 months after transfusion that are not attributable to changes related to an increase in age. Discussion: Our findings suggest that autologous cord blood transfusion does not appear to provide major systemic immunoregulatory benefits in children with autism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.